8-K current report · filed Nov 10, 2026

Inhibikase Therapeutics, Inc. (IKT) 8-K Current Report: November 10, 2026

Item 2.02Item EX-99.1IKT overview

Short answer

Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.

Inhibikase Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Corporate updates announced alongside quarterly results
  • Detailed financial figures and updates contained in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Phase 3 IMPROVE-PAH advancing: 28 countries approved and 79 of 180 planned sites activated
  • Part A interim safety readout planned for first half of 2027, a near-term clinical catalyst
  • Cash, equivalents and marketable securities $193.3M at September 30, 2026, with funding expected through Part B topline data assuming warrant exercise
  • Quarterly net loss $20.5M versus $11.9M, while R&D expense rose to $15.0M from $7.6M as trial activity accelerates
  • July financing raised $50M from 25,000,000 shares sold to RA Capital, followed by exchange of 18,030,000 shares for pre-funded warrants

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Inhibikase Therapeutics, Inc. 8-K filings

Get the next IKT 8-K as it lands

Follow IKT for push alerts, or ask the research agent what this filing means.